Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Northern Trust Corp acquired 489,735 shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during Q4, valued at approximately $162,000, increasing its ownership to 26.20%. Commonwealth Equity Services also purchased a stake worth $40,000. Analysts have mixed views on TNXP, with Wall Street Zen downgrading it to 'sell' while Noble Financial maintains an 'outperform' rating with a $70 target price. Tonix's stock rose 6.3% recently, with a market cap of $296.30 million and a reported EPS of -$2.84, beating estimates. The company focuses on developing therapeutics for human diseases.
Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 489,735 shares of the company's stock, valued at approximately $162,000. Northern Trust Corp owned about 26.20% of Tonix Pharmaceuticals at the end of the most recent reporting period.
Get Tonix Pharmaceuticals alerts:
- Pharma Frenzy: Volatility Ignites Biotech Sector
Separately, Commonwealth Equity Services LLC purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 82.26% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on TNXP. Wall Street Zen cut Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Noble Financial reissued an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th.
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
Get Our Latest Stock Report on Tonix Pharmaceuticals
Insider Transactions at Tonix Pharmaceuticals
In related news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the purchase, the chief executive officer now directly owns 4,005 shares of the company's stock, valued at $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.03% of the company's stock.
Tonix Pharmaceuticals Stock Up 6.3%
TNXP stock opened at $40.45 on Wednesday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $520.00. The business's 50-day moving average is $21.96 and its two-hundred day moving average is $22.55. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company has a market cap of $296.30 million, a price-to-earnings ratio of -0.01 and a beta of 1.63.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. As a group, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.
About Tonix Pharmaceuticals
(Free Report)Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
- Five stocks we like better than Tonix Pharmaceuticals
- Dividend Payout Ratio Calculator
- Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
- Asset Allocation Strategies in Volatile Markets
- Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next
- Comparing and Trading High PE Ratio Stocks
- Rocket Lab Expands Into Payloads: Should You Be Paying Attention?
Want to see what other hedge funds are holding TNXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
